JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fu, Y.
Right arrow Articles by Sharp, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fu, Y.
Right arrow Articles by Sharp, B. M.

Vol. 294, Issue 2, 458-465, August 2000

Systemic Nicotine Stimulates Dopamine Release in Nucleus Accumbens: Re-evaluation of the Role of N-Methyl-D-aspartate Receptors in the Ventral Tegmental Area1

Yitong Fu, Shannon G. Matta, Wenqing Gao, Victoria G. Brower and Burt M. Sharp

Department of Pharmacology, Health Science Center, University of Tennessee, Memphis, Tennessee

Systemic nicotine stimulates dopamine (DA) release in the nucleus accumbens (NAcc), and N-methyl-D-aspartate (NMDA) receptors in the ventral tegmental area (VTA) appear to be involved. However, it is not known whether the secretion of DA elicited by nicotine depends on the tonic and/or phasic activation of NMDA receptors by glutamate (Glu). To clarify this, in vivo microdialysis was conducted in freely moving, alert rats to measure DA and Glu overflows in the NAcc and Glu in the VTA. Nicotine (0.065, 0.09, or 0.135 mg/kg delivered i.v. at 0.09 mg/kg/60 s via a jugular cannula) dose dependently stimulated NAcc DA secretion (P < .05). However, 0.065 mg/kg nicotine failed to stimulate Glu release in the VTA, whereas higher doses of nicotine (>= 0.09 mg/kg) were effective (P < .05). Administering the competitive NMDA receptor antagonists, 2-amino-5-phosphonopentanoic acid (AP-5; 1 mM) or 0.2 mM cis-4-phosphonomethyl-2-piperidine carboxylic acid (CGS 19755) through the VTA probe, abolished NAcc DA release after 0.065 mg/kg nicotine (P < .01) and reduced the response to 0.09 mg/kg nicotine. Therefore, the NAcc DA response to a relatively low dose of nicotine depends on the tonic activation of NMDA receptors in the VTA. In contrast, infusing 1 mM 2-amino-5-phosphonopentanoic acid or 1 mM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an alpha -amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor antagonist, into the NAcc through the microdialysis probe had no effect on NAcc DA secretion in response to 0.09 mg/kg nicotine. These findings, coupled with data showing that Glu secretion in the VTA was stimulated only by higher doses of nicotine, indicate that the phasic release of VTA Glu is involved in the NAcc DA response to higher doses of nicotine (>= 0.09 mg/kg).

1 This study was supported by National Institute on Drub Abuse Grant DA03977 (to B.M.S.).

0022-3565/00/2942-0458$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
H. Cassaday, B. Finger, and R. Horsley
Methylphenidate and nicotine focus responding to an informative discrete CS over successive sessions of appetitive conditioning
J Psychopharmacol, November 1, 2008; 22(8): 849 - 859.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
N. A. Addy, E. F. Fornasiero, T. R. Stevens, J. R. Taylor, and M. R. Picciotto
Role of Calcineurin in Nicotine-Mediated Locomotor Sensitization
J. Neurosci., August 8, 2007; 27(32): 8571 - 8580.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. R. Kosowski and S. Liljequist
The NR2B-Selective N-Methyl-D-aspartate Receptor Antagonist Ro 25-6981 [({+/-})-(R*,S*)-{alpha}-(4-Hydroxyphenyl)-{beta}-methyl-4-(phenylmethyl)-1-piperidine Propanol] Potentiates the Effect of Nicotine on Locomotor Activity and Dopamine Release in the Nucleus Accumbens
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 560 - 567.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. M. Sharp, M. Yatsula, and Y. Fu
Effects of Galantamine, a Nicotinic Allosteric Potentiating Ligand, on Nicotine-Induced Catecholamine Release in Hippocampus and Nucleus Accumbens of Rats
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1116 - 1123.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. L. Parker, Y. Fu, K. McAllen, J. Luo, J. M. McIntosh, J. M. Lindstrom, and B. M. Sharp
Up-Regulation of Brain Nicotinic Acetylcholine Receptors in the Rat during Long-Term Self-Administration of Nicotine: Disproportionate Increase of the {alpha}6 Subunit
Mol. Pharmacol., March 1, 2004; 65(3): 611 - 622.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Cohen, O. E. Bergis, F. Galli, A. W. Lochead, S. Jegham, B. Biton, J. Leonardon, P. Avenet, F. Sgard, F. Besnard, et al.
SSR591813, a Novel Selective and Partial {alpha}4{beta}2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 407 - 420.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. L. Cornish, M. Nakamura, and P. W. Kalivas
Dopamine-Independent Locomotion Following Blockade of N-Methyl-D-aspartate Receptors in the Ventral Tegmental Area
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 226 - 233.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.